ECEESPE2025 ePoster Presentations Growth Axis and Syndromes (132 abstracts)
Adherence and its key-driving factors to growth hormone treatment in children with growth disorders: the french SCOPE study
Michel Polak 1,2 , Bouhours-Nouet Natacha 3 , Paula van Dommelen 4 , Lilian Arnaud 5 , Sophie Berger 6 , Claire Castello-bridoux 6 , Quentin Le Masne 7 , Melissande Simonin 5 , Raphael Untereiner 8 , Ekaterina Koledova 9 , Maithé Tauber 10 & Agnès Linglart 11
1Department of Paediatric Endocrinology, Diabetology and Gynaecology, Necker Children’s University Hospital, Assistance Publique Hôpitaux de Paris (APHP), Paris, France; 2Université Paris Cité, Paris, France; 3Department of Paediatric Endocrinology and Diabetology, Angers University Hospital, Angers, France; 4The Netherlands Organization for Applied Scientific Research TNO, Leiden, Netherlands; 5Devices and Connected Solutions Engineering, Global Healthcare Operations, Ares Trading S.A. (an affiliate of Merck KGaA, Darmstadt, Germany), Eysins, Switzerland; 6Medical Affairs Department Endocrinology, Merck Santé S.A.S., (an affiliate of Merck Healthcare KGaA, Darmstadt, Germany), Lyon, France; 7Akkad SAS, Lyon, France; 8Department of Medical Affairs Endocrinology, Merck Serono S.A.S., (an affiliate of Merck Healthcare KGaA, Darmstadt, Germany), Lyon, France; 9Global Medical Affairs, Cardiometabolic and Endocrinology, Merck Healthcare KGaA, Darmstadt, Germany; 10Department of Paediatric Endocrinology, Obesity, Bone Diseases, Genetics and Gynaecology, Toulouse University Hospital, Toulouse, France; 11Paris Saclay University, Assistance Publique Hôpitaux de Paris (APHP), Department of Paediatric Endocrinology and Diabetology, Bicêtre Paris-Saclay Hospital, Le Kremlin-Bicêtre, France
JOINT1583
Background: For patients with growth disorders managed on recombinant human growth hormone (r-hGH) therapy, the Growzen™ ecosystem (previously Easypod® Connect) provides an innovative connected injection device transmitting adherence data, empowering healthcare professionals to monitor real-time patient adherence.
Aim: This SCOPE (Study and Collection of Observational data for Patients with Easypod® Connect) study aims to use 5-year data from Growzen™ ecosystem to evaluate adherence and its key-driving factors in patients with growth disorders from France.
Methods: Adherence data for patients aged 4–17 years at treatment start and <18 years were extracted from Growzen™ ecosystem between June 2018–December 2023. The following potential key-driving factors for adherence were assessed: indication (Growth Hormone Deficiency [GHD] and Small for Gestational age [SGA]), sex, age, and treatment regimen (7 vs 6 days/week).
Results: Adherence data from 481 patients (265 GHD, 157 SGA, 13 Turner Syndrome, 46 other/unknown indications) across 19 centers were analysed. Of these, 256 patients followed a regimen of 7 days/week and 225 patients followed a regimen of 6 days/week. Mean age at treatment start was 9.9 years in all patients, 10.5 and 8.8 years in patients with GHD and SGA respectively. The proportion of high-level adherence (≥85%) was 85% across all patients and was similar between GHD and SGA patients. During the first 12–18 months, adherence levels were comparable for boys and girls, with nearly 90% high-level adherence. A slight difference in the adherence level was found between boys and girls over time, with a larger portion of girls having a high-level adherence after couple of years. A high-level adherence was observed in approximately 95% patients up to 5 years of age and 90% between 5 and 12 years. This decreased after the age of 12 years with 72% of patients having a high-level adherence at 17 years of age. The proportion of high-level adherence was 82% for 7 injections/week regimen and 88% for 6 injections/week regimen, but the difference was not statistically significant after adjustment for patient ages (10.5 years with 7 days/week, 9.3 years with 6 days/week).
Conclusion: The adherence level over the study period was high, demonstrating good engagement level of patients using the connected device for the daily administration of r-hGH therapy. Among all potential key-driving factors for adherence, the age at treatment start showed the highest impact on the level of adherence, emphasizing the need for early initiation of treatment for better outcomes.
Volume 110
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2025 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more